Formulations for pulmonary administration of anticancer agents to treat lung malignancies - PubMed (original) (raw)

Review

Formulations for pulmonary administration of anticancer agents to treat lung malignancies

Thiago C Carvalho et al. J Aerosol Med Pulm Drug Deliv. 2011 Apr.

Abstract

Chemotherapy plays a significant role both as primary and as supportive care for lung cancer treatment. The majority of currently available anticancer agents are administrated intravenously, causing side effects due to the systemic drug distribution. Alternatively, the bioavailability of orally administrated anticancer agents is usually compromised by the first-pass metabolism. Pulmonary administration may be a potential route for anticancer drug delivery to treat lung tumors, due to its site specific delivery, avoidance of first-pass metabolism, possibility of fewer side effects, and improved comfort for cancer patients using a needle-free delivery device. However, to attain an effective inhalational delivery, there is a requirement to design a formulation with appropriate aerodynamic properties with well-suited excipients. This review article explores work to date related to the formulations developed for pulmonary delivery of small molecule antineoplastic agents to treat primary and metastatic lung carcinomas. Ultimately, it highlights the importance of formulation design to define the role of inhalational chemotherapy.

PubMed Disclaimer

Similar articles

• Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
  Islam N, Richard D. Islam N, et al. Curr Cancer Drug Targets. 2019;19(3):162-178. doi: 10.2174/1568009618666180525083451. Curr Cancer Drug Targets. 2019. PMID: 29793407 Review.
• Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.
  Yu XY, Jin X, Shou ZX. Yu XY, et al. Drug Deliv. 2021 Dec;28(1):1995-2010. doi: 10.1080/10717544.2021.1981492. Drug Deliv. 2021. PMID: 34569401 Free PMC article. Review.
• Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
  Okuda T, Okamoto H. Okuda T, et al. Chem Pharm Bull (Tokyo). 2020;68(7):589-602. doi: 10.1248/cpb.c20-00086. Chem Pharm Bull (Tokyo). 2020. PMID: 32611996 Review.
• Aerosol Delivery in the Treatment of Lung Cancer.
  Storti C, Le Noci V, Sommariva M, Tagliabue E, Balsari A, Sfondrini L. Storti C, et al. Curr Cancer Drug Targets. 2015;15(7):604-12. doi: 10.2174/1568009615666150602143751. Curr Cancer Drug Targets. 2015. PMID: 26033086 Review.
• Aerosolized chemotherapy.
  Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lemarie E. Gagnadoux F, et al. J Aerosol Med Pulm Drug Deliv. 2008 Mar;21(1):61-70. doi: 10.1089/jamp.2007.0656. J Aerosol Med Pulm Drug Deliv. 2008. PMID: 18518832 Review.

Cited by

• Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.
  Willis L, Hayes D Jr, Mansour HM. Willis L, et al. Lung. 2012 Jun;190(3):251-62. doi: 10.1007/s00408-011-9360-x. Epub 2012 Jan 25. Lung. 2012. PMID: 22274758 Review.
• Inhaled Medicines for Targeting Non-Small Cell Lung Cancer.
  Al Khatib AO, El-Tanani M, Al-Obaidi H. Al Khatib AO, et al. Pharmaceutics. 2023 Dec 14;15(12):2777. doi: 10.3390/pharmaceutics15122777. Pharmaceutics. 2023. PMID: 38140117 Free PMC article. Review.
• The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses.
  Rosière R, Berghmans T, De Vuyst P, Amighi K, Wauthoz N. Rosière R, et al. Cancers (Basel). 2019 Mar 7;11(3):329. doi: 10.3390/cancers11030329. Cancers (Basel). 2019. PMID: 30866545 Free PMC article. Review.
• Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.
  Gupta C, Jaipuria A, Gupta N. Gupta C, et al. Pharmaceutics. 2022 Dec 31;15(1):139. doi: 10.3390/pharmaceutics15010139. Pharmaceutics. 2022. PMID: 36678768 Free PMC article. Review.
• Aerosolization of Nanotherapeutics as a Newly Emerging Treatment Regimen for Peritoneal Carcinomatosis.
  Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K. Shariati M, et al. Cancers (Basel). 2019 Jun 28;11(7):906. doi: 10.3390/cancers11070906. Cancers (Basel). 2019. PMID: 31261685 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information